Literature DB >> 2207764

Mechanisms of action and clinical uses of estramustine.

R Benson1, B Hartley-Asp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2207764     DOI： 10.3109/07357909009012056

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  9 in total

1.  Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Authors:  Yu-Ning Wong; Judith Manola; Gary R Hudes; Bruce J Roth; Judd W Moul; Andrea M Barsevick; Richard M Scher; Michael J Volk; David J Vaughn; Stephen D Williams; Michael J Fisch; David Cella; Michael A Carducci; George Wilding
Journal:  Clin Genitourin Cancer       Date:  2017-10-16       Impact factor: 2.872

Review 2.  [Therapy of hormone-refractory prostate cancer].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2005-12       Impact factor: 0.639

Review 3.  [Treatment options for hormone-refractory prostate cancer].

Authors:  A Heidenreich; C H Ohlmann
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

4.  Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.

Authors:  Yasutomo Nakai; Kazuo Nishimura; Masashi Nakayama; Motohide Uemura; Hitoshi Takayama; Norio Nonomura; Akira Tsujimura
Journal:  Int J Clin Oncol       Date:  2013-03-01       Impact factor: 3.402

Review 5.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

Review 6.  [Chemotherapy of hormone refractory prostate carcinoma].

Authors:  M P Wirth; J Nippgen
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

Review 7.  Chemotherapy of prostate cancer: present and future.

Authors:  Donald Trump; Yiu-Keung Lau
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

8.  Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer.

Authors:  W Albrecht; H Van Poppel; S Horenblas; G Mickisch; A Horwich; V Serretta; G Casetta; J M Maréchal; W G Jones; S Kalman; R Sylvester
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

Review 9.  Development and Clinical Application of Phosphorus-Containing Drugs.

Authors:  Hanxiao Yu; He Yang; Enxue Shi; Wenjun Tang
Journal:  Med Drug Discov       Date:  2020-08-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.